

PATENT COOPERATION TREATY
PCT
THIRD PARTY OBSERVATION
(PCT Administrative Instructions Part 8)

Applicant's or agent's file reference 52524-0004WO1	
International application number PCT/US2021/061235	International filing date (day/month/year) 30 Nov 2021 (30/11/2021)
Applicant WESANA HEALTH INC. (+2)	
Third party observation submitted by Taylor KURTZWEIL	Observation submitted on behalf of Porta Sophia Psychedelic Prior Art Library - www.portasophia.org
Date of submission(day/month/year) 17 Aug 2022 (17/08/2022)	Language of observation English

Basis and contents of observation

1. The observation is made on the basis of the claims in the international application as filed.
2. The observation comprises:
References to documents: 5
Uploaded copies of documents: 5
3. Further explanations:
Uploaded copies of documents: 0

Citation # 1 (Patent/utility model) (# uploaded documents: 1):

Country code: WO	Publication number: 2021/072530	Document kind code: A1	
Patent Applicant/Patent Owner: Tassili Life Sciences, Corp.		Title of invention: Controlled Release Formulations of Multiple Active Pharmaceutical Agents, and Psilocybe-derived Agen	
Link to document: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021072530&_cid=P11-L6O0WM-92798-1			
Publication Date: 22 Apr 2021 (22/04/2021)	Filing Date: 14 Oct 2020 (14/10/2020)	Priority Date: 15 Oct 2019 (15/10/2019)	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: Claims 14, 21, 22, 24, 25, 26		Relevant to Claims: 1, 2, 46, 47, 55, 56	
Brief explanation of relevance: <p>From Claim 14: "A method for alleviating one or more symptoms of mTBI with PTSD, said method comprising administering to a subject suffering from mTBI with PTSD a psilocybe-derived agent in combination with a cannabis-derived agent."; relevant to WO2022115796 claims 1, 2, 55, 78, 79</p> <p>From Claim 21: "The method of any of claims 14 through 20, wherein the psilocybe-derived agent is psilocybin."; relevant to WO2022115796claim 1</p> <p>From Claim 22: "The method of any of claim 14 through 21, wherein the cannabis-derived agent is cannabidiol."; relevant to WO2022115796 claims 46, 47</p> <p>From Claim 24: "Use of a psilocybe-derived agent in combination with a cannabis-derived agent for alleviating one or more symptoms of mTBI with PTSD."; relevant to WO2022115796 claims 2, 55, 79</p> <p>From Claim 25: "The use of claim 24, wherein the one or more symptoms is selected from intrusive memories, nightmares, a sense of reliving the trauma, or psychological or physiological distress when reminded of the trauma, active avoidance of thoughts, feelings, or reminders of the trauma, inability to recall some aspect of the trauma, withdrawal from others, or emotional numbing, insomnia, irritability, difficulty concentrating, hypervigilance, or heightened startle response."; relevant to WO2022115796 claims 2, 55, 56, 79</p>			

Citation # 2 (Patent/utility model) (# uploaded documents: 1):

Country code: US	Publication number: 20190192498	Document kind code: A1	
Patent Applicant/Patent Owner: Stamets; Paul Edward		Title of invention: Psilocybin Compositions	
Link to document: https://patentscope.wipo.int/search/en/detail.jsf?docId=US245418932&_cid=P11-L6OIN2-54920-1			
Publication Date: 27 Jun 2019 (27/06/2019)	Filing Date: 26 Feb 2019 (26/02/2019)	Priority Date: 23 Jul 2016 (23/07/2016)	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: Claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 16		Relevant to Claims: Multiple - see below	

Brief explanation of relevance:

Relevant to claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 17, 18, 19, 28, 29, 31, 33, 42, 44, 45, 46, 47, 48, 49, 54, 55, 56, 79, 80, 81, 82

From Claim 1: "A composition comprising: 0.1 mg to 10 mg of psilocybin, psilocin, baeocystin, norbaeocystin, salts thereof, or combinations thereof, or about 0.1 gram to 1 gram of psilocybin mushrooms, or combinations thereof; 0.1 mg to 200 mg of erinacines, hericenones or combinations thereof; and 1 mg to 200 mg of niacin."; relevant to WO2022115796 claims 5, 8, 9, 10, 11, 12, 16, 17, 19, 28, 31, 33, 48

From Claim 2: "The composition method of claim 1, wherein the composition further comprises: ... Turmeric (*Curcuma longa*) ... *Cannabis sativa*, *Cannabis indica* or *Cannabis ruderalis*, or combinations thereof."; relevant to WO2022115796 claims 31, 42, 44, 46, 47, 48, 49

From Claim 3: "The composition of claim 1, wherein the composition further comprises: mycelium of ... *Cordyceps*, *Ganoderma*, *Grifola*, *Herichium* ... or *Phellinus* fungi, or combinations thereof; a mycelium extract of ... *Cordyceps*, *Ganoderma*, *Grifola*, *Herichium*, ... *Phellinus*, or combinations; or a fruitbody extract of ... *Cordyceps*, *Ganoderma*, *Grifola*, *Herichium*, ... or *Phellinus*, or combinations thereof."; relevant to WO2022115796 claims 18, 19, 28, 29, 33, 45

From Claim 4: "A method for improving neurological health of an animal comprising: administering the composition of claim 1."; relevant to WO2022115796 claims 1, 2, 4, 54, 55, 56, 79, 80, 81, 82

From Claim 5: "The method of claim 4, wherein the animal is a human."; relevant to WO2022115796 claims 1, 2, 4, 54, 55, 56, 79, 80, 81, 82

From Claim 6: "The method of claim 5, wherein the administration results in one or more of improved memory and cognition, improved motor skills and coordination, improved sensory function, improved learning, or promotion of neurogenesis."; relevant to WO2022115796 claims 1, 2, 55, 56, 79

From Claim 7: "A composition comprising: about 0.1 mg to 10 mg of psilocybin, psilocin, baeocystin, norbaeocystin, or salts thereof, or about 0.1 gram to 1 gram of psilocybin mushrooms, or combinations thereof; about 0.1 mg to 200 mg of erinacines, hericenones, or combinations thereof; about 100 mg of *Cannabis* extracts comprising cannabidiol; and about 1 mg to 200 mg of niacin."; relevant to WO2022115796 claims 3, 5, 6, 7, 31, 49

From Claim 8: "The composition method of claim 7, wherein the composition comprises: about 0.6 mg to 10 mg of one or more of psilocybin, psilocin, baeocystin, norbaeocystin, salts thereof, or combinations thereof; about 20 mg to 200 mg of one or more of erinacines, hericenones, or combinations thereof; about 100 mg of *Cannabis* extracts comprising cannabidiol; and about 50 mg to 200 mg of niacin."; relevant to WO2022115796 claims 3, 5, 6, 7, 31, 49

From Claim 9: "The composition method of claim 7, wherein the composition comprises: about 0.9 mg to 10 mg of one or more of psilocybin, psilocin, baeocystin, norbaeocystin, salts thereof, or combinations thereof; about 50 mg to 200 mg of one or more of erinacines, hericenones, or combinations thereof; about 100 mg of *Cannabis* extracts comprising cannabidiol; and about 50 mg to 200 mg of niacin."; relevant to WO2022115796 claims 3, 5, 6, 7, 31, 49

From Claim 16: "A composition comprising: mycelia, fruitbodies, or extracts thereof of *Cordyceps*, *Ganoderma*, *Grifola*, *Herichium*, or combinations thereof; and *Cannabis* extracts comprising cannabidiol, tetrahydrocannabinol, or combinations thereof."; relevant to WO2022115796 claims 31, 42, 46

Citation # 3 (Patent/utility model) (# uploaded documents: 1):

Country code: WO	Publication number: 2018/135943	Document kind code: A1	
Patent Applicant/Patent Owner: Procare Beheer B.V.	Title of invention: Psilocybin and/or Psilocin in Combination with Cannabinoids and/or Terpenes		
Link to document: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018135943&_cid=P11-L6OITG-56679-1			
Publication Date: 26 Jul 2018 (26/07/2018)	Filing Date: 18 Jan 2018 (18/01/2018)	Priority Date: 18 Jan 2017 (18/01/2017)	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: Claims 1, 2, 3, 5, 8, 9, 10, 12, 14, 15		Relevant to Claims: Multiple - see below	

Brief explanation of relevance:

Relevant to claims 2, 3, 4, 8, 9, 10, 11, 12, 13, 14, 15, 31, 34, 35, 42, 46, 47, 48, 53, 55, 56, 62, 63, 64, 65, 66, 78, 79, 80, 81, 82, 85, 86, 87, 88

From Claim 1: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use in the prevention or treatment of a psychological disorder, wherein the at least one cannabinoid and/or at least one terpene is administered separately, sequentially or simultaneously to the psilocybin and/or psilocin."; relevant to WO2022115796 claims 3, 31, 42, 46, 47, 48, 78

From Claim 2: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use according to claim 1, wherein the psychological disorder is chosen from depression ... anxiety disorder, panic disorder, panic attacks, agoraphobia, attention deficit syndrome ..." relevant to WO2022115796 claims 2, 4, 55, 56, 79, 80, 81, 82,

From Claim 3: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use in the prevention or treatment of a brain disorder, wherein the at least one cannabinoid and/or at least one terpene is administered separately, sequentially or simultaneously to the psilocybin and/or psilocin."; relevant to WO2022115796 claims 2, 55, 79

From Claim 5: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use according to any of the preceding claims, wherein the at least one cannabinoid is at least one, two or three chosen from the group consisting of cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannabivarin (THCV); tetrahydrocannabivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA)."; relevant to WO2022115796 claims 3, 31, 42, 46, 47, 78

From Claim 8: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use according to any of the previous claims, wherein the at least one cannabinoid is present in a pure form."; relevant to WO2022115796claim 15

From Claim 9: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use according to any of the previous claims, wherein the at least one cannabinoid is present in a synthetic form."; relevant to WO2022115796claim 14

From Claim 10: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use according to any of the previous claims, wherein the psilocybin and/or psilocin are present in the form of an extract from a mushroom and/or truffle (sclerotium), preferably from the genus .. P. cubensis ..."; relevant to WO2022115796 claims 13, 53, 66, 88

From Claim 12: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use according to any of the previous claims, wherein the psilocybin and/or psilocin are present in a synthetic form."; relevant to WO2022115796 claims 8, 9, 10, 34, 35, 62, 63, 85, 11, 12, 62, 63, 64, 65, 86, 87

From Claim 14: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use in the prevention and/or treatment of ... delirium, amnesic disorders and other cognitive disorders, ... mood disorders, anxiety disorders, somatoform disorders, factitious disorders, dissociative disorders, eating disorders, sleep disorders, impulse control disorders, adjustment disorders, or personality disorders."; relevant to WO2022115796 claims 2, 55, 79

From Claim 15: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use in the prevention and/or treatment of... depression... generalized anxiety disorder... pain disorder... posttraumatic stress disorder..."; relevant to WO2022115796 claims 2, 55, 79

Citation # 4 (Patent/utility model) (# uploaded documents: 1):

Country code: WO	Publication number: 2021/207824	Document kind code: A1	
Patent Applicant/Patent Owner: Revive Therapeutics LTD.		Title of invention: Use of Psilocybin in the Treatment of Neurological Brain Injury and Migraines	
Link to document:			
Publication Date: 21 Oct 2021 (21/10/2021)	Filing Date: 18 Mar 2021 (18/03/2021)	Priority Date: 17 Apr 2020 (17/04/2020)	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: Claims 1, 7, 8; Detailed Description pages 7-9		Relevant to Claims: Multiple - see below	
Brief explanation of relevance: Relevant to claims 1, 2, 4, 5, 6, 7, 21, 22, 24, 28, 33, 51, 52, 38, 57, 58, 59, 60, 61 From Claim 1: "A method for the treatment of a brain injury or a migraine in a mammal comprising administering a therapeutically effective amount of psilocybin or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients to a mammal in need thereof."; relevant to WO2022115796 claims 1, 2, 4, 28, 33 From Claim 7: "The method of any one of claims 1 to 6, wherein the brain injury is selected from the group consisting of a mild brain injury or traumatic brain injury."; relevant to WO2022115796 claims 1, 2, 28, 33, 52 From Claim 8: "The method of claim 7, wherein the brain injury is selected from the group consisting of a concussion, a stroke and Alzheimer's."; relevant to WO2022115796 claims 1, 2, 28, 33, 51, 52 From Detailed Description (page 9): "However, the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly, the optimum dosage may be determined by the practitioner who is treating any particular patient. In another embodiment, the optimal dose may be higher."; relevant to WO2022115796 claims 5, 6, 7, 21, 22, 24, 38, 57, 58, 59, 60, 61			

Citation # 5 (Patent/utility model) (# uploaded documents: 1):

Country code: WO	Publication number: 2020/157569	Document kind code: A1	
Patent Applicant/Patent Owner: Diamond Therapeutics Inc.		Title of invention: Methods and Compositions Comprising a 5HT Receptor Agonist for the Treatment of Psychological, Cogni	
Link to document: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020157569&_cid=P11-L6WM01-84838-1			
Publication Date: 06 Aug 2020 (06/08/2020)	Filing Date: 29 Jan 2020 (29/01/2020)	Priority Date: 30 Jan 2019 (30/01/2019)	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: Claims 3, 22, 30, 36, 37, 38, 42, 43; Summary paragraph 10		Relevant to Claims: Multiple - see below	

Brief explanation of relevance:

From Claim 3: "The method of any one of the preceding claims, wherein the 5HT receptor agonist or a pharmaceutically acceptable salt, solvate, metabolite, derivative, or prodrug thereof is present in an amount of from about 0.1 mg to about 50 mg (e.g. about 0.1 mg to about 10 mg, about 0.2 mg to about 5 mg, about 10 mg to about 50 mg, or the like)."; relevant to WO2022115796 claims 5, 6, 7, 36, 43, 57, 58, 59, 60, 61, 106, 107

From Claim 22: "The method of claim 18, wherein the second agent is a 5HT receptor antagonist."; relevant to WO2022115796 claims 32, 50, 67, 68, 69, 70, 71, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100

From Claim 30: "The method of any one of the preceding claims, wherein the pharmaceutical composition is administered to a subject in need thereof once a day, every alternate day, three times a week, twice a week, once a week, every other week, two weeks per month, three weeks per month, once a month, twice a month or three times per month. 31. The method of any one of the preceding claims, wherein the pharmaceutical composition is administered about once a day." relevant to WO2022115796 claims 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 73, 74, 75, 76, 77, 83, 84

From Claim 36: "The method of any one of the preceding claims, wherein the neurological condition is a neurological disorder."; relevant to WO2022115796 claims 1, 2, 54, 55

From Claim 37: "The method of any one of the preceding claims, wherein the neurological condition is a neurocognitive disorder."; relevant to WO2022115796 claims 1, 2, 3, 54, 55, 56

From Claim 38: "The method of any one of the preceding claims, wherein the symptoms of the neurological condition are physical, behavioral, emotional, mental or a combination thereof."; relevant to WO2022115796 claims 1, 2, 3, 54, 55, 56

From Claim 42: "The method of any one of claims 1-38, wherein the neurological condition is pain (e.g. chronic pain)."; relevant to WO2022115796 claims 2, 55

From Claim 43: "The method of any one of claims 1-38, wherein the neurological condition is depression, bipolar disorder, anxiety, social anxiety, post-traumatic stress disorder (PTSD), panic disorder, phobia, schizophrenia, psychopathy, or antisocial personality disorder."; relevant to WO2022115796 claims 2, 4, 55, 56

From Summary Paragraph 10: "Also provided herein is a method of treating the symptoms of a neurological condition in a subject suffering from or susceptible to the neurological condition, comprising administering to the subject a pharmaceutical composition comprising: a) a therapeutically effective amount of one or more 5HT receptor agonist (e.g., psilocin) or a pharmaceutically acceptable salt, solvate, metabolite, derivative, or prodrug thereof (e.g., psilocybin); and b) a pharmaceutically acceptable excipient." Relevant to WO2022115796 claims 100, 101, 102, 103, 104, 105

PATENT COOPERATION TREATY
PCT
THIRD PARTY OBSERVATION
(PCT Administrative Instructions Part 8)

Applicant's or agent's file reference 52524-0004WO1	
International application number PCT/US2021/061235	International filing date (day/month/year) 30 Nov 2021 (30/11/2021)
Applicant WESANA HEALTH INC. (+2)	
Third party observation submitted by Taylor KURTZWEIL	Observation submitted on behalf of Porta Sophia Psychedelic Prior Art Library - www.portasophia.org
Date of submission(day/month/year) 17 Aug 2022 (17/08/2022)	Language of observation English

Basis and contents of observation

1. The observation is made on the basis of the claims in the international application as filed.
2. The observation comprises:
References to documents: 5
Uploaded copies of documents: 5
3. Further explanations:
Uploaded copies of documents: 0

Pending processing

Citation # 1 (Patent/utility model) (# uploaded documents: 1):

Country code: WO	Publication number: 2021/072530	Document kind code: A1	
Patent Applicant/Patent Owner: Tassili Life Sciences, Corp.		Title of invention: Controlled Release Formulations of Multiple Active Pharmaceutical Agents, and Psilocybe-derived Agen	
Link to document: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021072530&_cid=P11-L6O0WM-92798-1			
Publication Date: 22 Apr 2021 (22/04/2021)	Filing Date: 14 Oct 2020 (14/10/2020)	Priority Date: 15 Oct 2019 (15/10/2019)	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: Claims 14, 21, 22, 24, 25, 26		Relevant to Claims: 1, 2, 46, 47, 55, 56	
Brief explanation of relevance: <p>From Claim 14: "A method for alleviating one or more symptoms of mTBI with PTSD, said method comprising administering to a subject suffering from mTBI with PTSD a psilocybe-derived agent in combination with a cannabis-derived agent."; relevant to WO2022115796 claims 1, 2, 55, 78, 79</p> <p>From Claim 21: "The method of any of claims 14 through 20, wherein the psilocybe-derived agent is psilocybin."; relevant to WO2022115796claim 1</p> <p>From Claim 22: "The method of any of claim 14 through 21, wherein the cannabis-derived agent is cannabidiol."; relevant to WO2022115796 claims 46, 47</p> <p>From Claim 24: "Use of a psilocybe-derived agent in combination with a cannabis-derived agent for alleviating one or more symptoms of mTBI with PTSD."; relevant to WO2022115796 claims 2, 55, 79</p> <p>From Claim 25: "The use of claim 24, wherein the one or more symptoms is selected from intrusive memories, nightmares, a sense of reliving the trauma, or psychological or physiological distress when reminded of the trauma, active avoidance of thoughts, feelings, or reminders of the trauma, inability to recall some aspect of the trauma, withdrawal from others, or emotional numbing, insomnia, irritability, difficulty concentrating, hypervigilance, or heightened startle response."; relevant to WO2022115796 claims 2, 55, 56, 79</p>			

Citation # 2 (Patent/utility model) (# uploaded documents: 1):

Country code: US	Publication number: 20190192498	Document kind code: A1	
Patent Applicant/Patent Owner: Stamets; Paul Edward		Title of invention: Psilocybin Compositions	
Link to document: https://patentscope.wipo.int/search/en/detail.jsf?docId=US245418932&_cid=P11-L6OIN2-54920-1			
Publication Date: 27 Jun 2019 (27/06/2019)	Filing Date: 26 Feb 2019 (26/02/2019)	Priority Date: 23 Jul 2016 (23/07/2016)	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: Claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 16		Relevant to Claims: Multiple - see below	

Brief explanation of relevance:

Relevant to claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 17, 18, 19, 28, 29, 31, 33, 42, 44, 45, 46, 47, 48, 49, 54, 55, 56, 79, 80, 81, 82

From Claim 1: "A composition comprising: 0.1 mg to 10 mg of psilocybin, psilocin, baeocystin, norbaeocystin, salts thereof, or combinations thereof, or about 0.1 gram to 1 gram of psilocybin mushrooms, or combinations thereof; 0.1 mg to 200 mg of erinacines, hericenones or combinations thereof; and 1 mg to 200 mg of niacin."; relevant to WO2022115796 claims 5, 8, 9, 10, 11, 12, 16, 17, 19, 28, 31, 33, 48

From Claim 2: "The composition method of claim 1, wherein the composition further comprises: ... Turmeric (*Curcuma longa*) ... *Cannabis sativa*, *Cannabis indica* or *Cannabis ruderalis*, or combinations thereof."; relevant to WO2022115796 claims 31, 42, 44, 46, 47, 48, 49

From Claim 3: "The composition of claim 1, wherein the composition further comprises: mycelium of ... *Cordyceps*, *Ganoderma*, *Grifola*, *Herichium* ... or *Phellinus* fungi, or combinations thereof; a mycelium extract of ... *Cordyceps*, *Ganoderma*, *Grifola*, *Herichium*, ... *Phellinus*, or combinations; or a fruitbody extract of ... *Cordyceps*, *Ganoderma*, *Grifola*, *Herichium*, ... or *Phellinus*, or combinations thereof."; relevant to WO2022115796 claims 18, 19, 28, 29, 33, 45

From Claim 4: "A method for improving neurological health of an animal comprising: administering the composition of claim 1."; relevant to WO2022115796 claims 1, 2, 4, 54, 55, 56, 79, 80, 81, 82

From Claim 5: "The method of claim 4, wherein the animal is a human."; relevant to WO2022115796 claims 1, 2, 4, 54, 55, 56, 79, 80, 81, 82

From Claim 6: "The method of claim 5, wherein the administration results in one or more of improved memory and cognition, improved motor skills and coordination, improved sensory function, improved learning, or promotion of neurogenesis."; relevant to WO2022115796 claims 1, 2, 55, 56, 79

From Claim 7: "A composition comprising: about 0.1 mg to 10 mg of psilocybin, psilocin, baeocystin, norbaeocystin, or salts thereof, or about 0.1 gram to 1 gram of psilocybin mushrooms, or combinations thereof; about 0.1 mg to 200 mg of erinacines, hericenones, or combinations thereof; about 100 mg of *Cannabis* extracts comprising cannabidiol; and about 1 mg to 200 mg of niacin."; relevant to WO2022115796 claims 3, 5, 6, 7, 31, 49

From Claim 8: "The composition method of claim 7, wherein the composition comprises: about 0.6 mg to 10 mg of one or more of psilocybin, psilocin, baeocystin, norbaeocystin, salts thereof, or combinations thereof; about 20 mg to 200 mg of one or more of erinacines, hericenones, or combinations thereof; about 100 mg of *Cannabis* extracts comprising cannabidiol; and about 50 mg to 200 mg of niacin."; relevant to WO2022115796 claims 3, 5, 6, 7, 31, 49

From Claim 9: "The composition method of claim 7, wherein the composition comprises: about 0.9 mg to 10 mg of one or more of psilocybin, psilocin, baeocystin, norbaeocystin, salts thereof, or combinations thereof; about 50 mg to 200 mg of one or more of erinacines, hericenones, or combinations thereof; about 100 mg of *Cannabis* extracts comprising cannabidiol; and about 50 mg to 200 mg of niacin."; relevant to WO2022115796 claims 3, 5, 6, 7, 31, 49

From Claim 16: "A composition comprising: mycelia, fruitbodies, or extracts thereof of *Cordyceps*, *Ganoderma*, *Grifola*, *Herichium*, or combinations thereof; and *Cannabis* extracts comprising cannabidiol, tetrahydrocannabinol, or combinations thereof."; relevant to WO2022115796 claims 31, 42, 46

Citation # 3 (Patent/utility model) (# uploaded documents: 1):

Country code: WO	Publication number: 2018/135943	Document kind code: A1	
Patent Applicant/Patent Owner: Procare Beheer B.V.		Title of invention: Psilocybin and/or Psilocin in Combination with Cannabinoids and/or Terpenes	
Link to document: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018135943&_cid=P11-L6OITG-56679-1			
Publication Date: 26 Jul 2018 (26/07/2018)	Filing Date: 18 Jan 2018 (18/01/2018)	Priority Date: 18 Jan 2017 (18/01/2017)	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: Claims 1, 2, 3, 5, 8, 9, 10, 12, 14, 15		Relevant to Claims: Multiple - see below	

Pending processing

Brief explanation of relevance:

Relevant to claims 2, 3, 4, 8, 9, 10, 11, 12, 13, 14, 15, 31, 34, 35, 42, 46, 47, 48, 53, 55, 56, 62, 63, 64, 65, 66, 78, 79, 80, 81, 82, 85, 86, 87, 88

From Claim 1: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use in the prevention or treatment of a psychological disorder, wherein the at least one cannabinoid and/or at least one terpene is administered separately, sequentially or simultaneously to the psilocybin and/or psilocin."; relevant to WO2022115796 claims 3, 31, 42, 46, 47, 48, 78

From Claim 2: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use according to claim 1, wherein the psychological disorder is chosen from depression ... anxiety disorder, panic disorder, panic attacks, agoraphobia, attention deficit syndrome ..." relevant to WO2022115796 claims 2, 4, 55, 56, 79, 80, 81, 82,

From Claim 3: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use in the prevention or treatment of a brain disorder, wherein the at least one cannabinoid and/or at least one terpene is administered separately, sequentially or simultaneously to the psilocybin and/or psilocin."; relevant to WO2022115796 claims 2, 55, 79

From Claim 5: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use according to any of the preceding claims, wherein the at least one cannabinoid is at least one, two or three chosen from the group consisting of cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannabivarin (THCV); tetrahydrocannabivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA)."; relevant to WO2022115796 claims 3, 31, 42, 46, 47, 78

From Claim 8: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use according to any of the previous claims, wherein the at least one cannabinoid is present in a pure form."; relevant to WO2022115796claim 15

From Claim 9: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use according to any of the previous claims, wherein the at least one cannabinoid is present in a synthetic form."; relevant to WO2022115796claim 14

From Claim 10: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use according to any of the previous claims, wherein the psilocybin and/or psilocin are present in the form of an extract from a mushroom and/or truffle (sclerotium), preferably from the genus .. *P. cubensis* ..."; relevant to WO2022115796 claims 13, 53, 66, 88

From Claim 12: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use according to any of the previous claims, wherein the psilocybin and/or psilocin are present in a synthetic form."; relevant to WO2022115796 claims 8, 9, 10, 34, 35, 62, 63, 85, 11, 12, 62, 63, 64, 65, 86, 87

From Claim 14: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use in the prevention and/or treatment of ... delirium, amnesic disorders and other cognitive disorders, ... mood disorders, anxiety disorders, somatoform disorders, factitious disorders, dissociative disorders, eating disorders, sleep disorders, impulse control disorders, adjustment disorders, or personality disorders."; relevant to WO2022115796 claims 2, 55, 79

From Claim 15: "Psilocybin and/or psilocin in combination with at least one cannabinoid and/or at least one terpene for use in the prevention and/or treatment of... depression... generalized anxiety disorder... pain disorder... posttraumatic stress disorder..."; relevant to WO2022115796 claims 2, 55, 79

Citation # 4 (Patent/utility model) (# uploaded documents: 1):

Country code: WO	Publication number: 2021/207824	Document kind code: A1	
Patent Applicant/Patent Owner: Revive Therapeutics LTD.		Title of invention: Use of Psilocybin in the Treatment of Neurological Brain Injury and Migraines	
Link to document:			
Publication Date: 21 Oct 2021 (21/10/2021)	Filing Date: 18 Mar 2021 (18/03/2021)	Priority Date: 17 Apr 2020 (17/04/2020)	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: Claims 1, 7, 8; Detailed Description pages 7-9		Relevant to Claims: Multiple - see below	
Brief explanation of relevance: Relevant to claims 1, 2, 4, 5, 6, 7, 21, 22, 24, 28, 33, 51, 52, 38, 57, 58, 59, 60, 61 From Claim 1: "A method for the treatment of a brain injury or a migraine in a mammal comprising administering a therapeutically effective amount of psilocybin or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents and excipients to a mammal in need thereof."; relevant to WO2022115796 claims 1, 2, 4, 28, 33 From Claim 7: "The method of any one of claims 1 to 6, wherein the brain injury is selected from the group consisting of a mild brain injury or traumatic brain injury."; relevant to WO2022115796 claims 1, 2, 28, 33, 52 From Claim 8: "The method of claim 7, wherein the brain injury is selected from the group consisting of a concussion, a stroke and Alzheimer's."; relevant to WO2022115796 claims 1, 2, 28, 33, 51, 52 From Detailed Description (page 9): "However, the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly, the optimum dosage may be determined by the practitioner who is treating any particular patient. In another embodiment, the optimal dose may be higher."; relevant to WO2022115796 claims 5, 6, 7, 21, 22, 24, 38, 57, 58, 59, 60, 61			

Citation # 5 (Patent/utility model) (# uploaded documents: 1):

Country code: WO	Publication number: 2020/157569	Document kind code: A1	
Patent Applicant/Patent Owner: Diamond Therapeutics Inc.		Title of invention: Methods and Compositions Comprising a 5HT Receptor Agonist for the Treatment of Psychological, Cogni	
Link to document: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020157569&_cid=P11-L6WM01-84838-1			
Publication Date: 06 Aug 2020 (06/08/2020)	Filing Date: 29 Jan 2020 (29/01/2020)	Priority Date: 30 Jan 2019 (30/01/2019)	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: Claims 3, 22, 30, 36, 37, 38, 42, 43; Summary paragraph 10		Relevant to Claims: Multiple - see below	

Brief explanation of relevance:

From Claim 3: "The method of any one of the preceding claims, wherein the 5HT receptor agonist or a pharmaceutically acceptable salt, solvate, metabolite, derivative, or prodrug thereof is present in an amount of from about 0.1 mg to about 50 mg (e.g. about 0.1 mg to about 10 mg, about 0.2 mg to about 5 mg, about 10 mg to about 50 mg, or the like)."; relevant to WO2022115796 claims 5, 6, 7, 36, 43, 57, 58, 59, 60, 61, 106, 107

From Claim 22: "The method of claim 18, wherein the second agent is a 5HT receptor antagonist."; relevant to WO2022115796 claims 32, 50, 67, 68, 69, 70, 71, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100

From Claim 30: "The method of any one of the preceding claims, wherein the pharmaceutical composition is administered to a subject in need thereof once a day, every alternate day, three times a week, twice a week, once a week, every other week, two weeks per month, three weeks per month, once a month, twice a month or three times per month. 31. The method of any one of the preceding claims, wherein the pharmaceutical composition is administered about once a day." relevant to WO2022115796 claims 20, 21, 22, 23, 24, 25, 26, 27, 37, 38, 39, 40, 73, 74, 75, 76, 77, 83, 84

From Claim 36: "The method of any one of the preceding claims, wherein the neurological condition is a neurological disorder."; relevant to WO2022115796 claims 1, 2, 54, 55

From Claim 37: "The method of any one of the preceding claims, wherein the neurological condition is a neurocognitive disorder."; relevant to WO2022115796 claims 1, 2, 3, 54, 55, 56

From Claim 38: "The method of any one of the preceding claims, wherein the symptoms of the neurological condition are physical, behavioral, emotional, mental or a combination thereof."; relevant to WO2022115796 claims 1, 2, 3, 54, 55, 56

From Claim 42: "The method of any one of claims 1-38, wherein the neurological condition is pain (e.g. chronic pain)."; relevant to WO2022115796 claims 2, 55

From Claim 43: "The method of any one of claims 1-38, wherein the neurological condition is depression, bipolar disorder, anxiety, social anxiety, post-traumatic stress disorder (PTSD), panic disorder, phobia, schizophrenia, psychopathy, or antisocial personality disorder."; relevant to WO2022115796 claims 2, 4, 55, 56

From Summary Paragraph 10: "Also provided herein is a method of treating the symptoms of a neurological condition in a subject suffering from or susceptible to the neurological condition, comprising administering to the subject a pharmaceutical composition comprising: a) a therapeutically effective amount of one or more 5HT receptor agonist (e.g., psilocin) or a pharmaceutically acceptable salt, solvate, metabolite, derivative, or prodrug thereof (e.g., psilocybin); and b) a pharmaceutically acceptable excipient." Relevant to WO2022115796 claims 100, 101, 102, 103, 104, 105